Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(33.3%)
Phase 2
1(33.3%)
Phase 1
1(33.3%)
3Total
N/A(1)
Phase 2(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05694962Phase 2Unknown

Low-Dose Radiation Therapy for Severe COVID-19 Pneumonia

Role: collaborator

NCT03607357Not ApplicableCompleted

High Flow Nasal Oxygen and Acute Left Heart Failure

Role: collaborator

NCT02668068Phase 1Completed

A Study on Pneumoconiosis Treated With Whole-lung Lavage Combined With Mesenchymal Stem Cells

Role: collaborator

All 3 trials loaded